ArticleInfection and drug resistance2023
Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
- Clinical characteristics and risk factors ofFrontiers in microbiology · 2026Article
- Development and validation of a novel model based on hematological biomarkers for predicting risk factors and outcomes in cancer patients with carbapenem-resistant organism infection.Frontiers in public health · 2026Article
- Clinical Features of Multidrug-Resistant Gram-Negative Bacteremia: A Comparative Study of Cancer and Non-Cancer Patients.Microorganisms · 2025Article
- Ceftazidime-avibactam use in hematology patients: single-center experience.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Research and predictive analysis of the disease burden of bloodstream infectious diseases in China.BMC infectious diseases · 2025Article
- Risk Factors for Development and Mortality of Carbapenem-ResistantInfection and drug resistance · 2025Article
- [Real-time rectal swab Xpert Carba-R assay for early warning of CRO bloodstream infection in patients undergoing hematopoietic stem cell transplant: a clinical feasibility study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Occurrence of Plasmid-Mediated Quinolone Resistance and Carbapenemase-Encoding Genes inPathogens (Basel, Switzerland) · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the clinical characteristics and prognostic risk factors of carbapenem-resistant Methods: Medical records and drug susceptibility data of patients with hematologic malignancies complicated by CRPA bloodstream infections admitted to the Cancer Hospital of Zhengzhou University between January 1, 2018, and December 31, 2022, were retrospectively analyzed. Results: A total of 64 patients were included in the study, with a mortality rate of 37.5% (24/64) at 28 days after the occurrence of CRPA bloodstream infection. In Cox regression analysis, an absolute neutrophil count <0.5×10 Conclusion: Patients with hematologic neoplasms had high mortality from CRPA bloodstream infections, and admission to the intensive care unit, higher Pitt bacteremia score (PBS) scores, granulocyte deficiency, and granulocyte deficiency at discharge were independently associated with higher mortality. Early anti-infective treatment with ceftazidime-avibactam or polymyxin B may improve the clinical prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.